These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 8017474)

  • 1. Heart disease in the assessment and treatment of hypercholesterolemia: coronary artery disease and other atherosclerotic disease, family history, and left ventricular hypertrophy.
    Gotto AM
    Am J Med; 1994 Jun; 96(6A):9S-18S. PubMed ID: 8017474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular risk factors and lipoprotein profile in French Canadians with premature CAD: impact of the National Cholesterol Education Program II.
    McNicoll S; Latour Y; Rondeau C; Bouthillier D; Davignon J; Genest J
    Can J Cardiol; 1995 Feb; 11(2):109-16. PubMed ID: 7866933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic efficacy of the lipid-lowering armamentarium: the clinical benefits of aggressive lipid-lowering therapy.
    Hunninghake DB
    Am J Med; 1998 Feb; 104(2A):9S-13S. PubMed ID: 9550501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low high-density lipoprotein cholesterol and other coronary heart disease risk factors in patients with total cholesterol levels greater than 5.17 mmol/L (200 mg/dL) in family practice. A report from CEN.
    J Am Board Fam Pract; 1991; 4(5):285-97. PubMed ID: 1746296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of older persons with hypercholesterolemia with and without cardiovascular disease.
    Aronow WS
    J Gerontol A Biol Sci Med Sci; 2001 Mar; 56(3):M138-45. PubMed ID: 11253155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-density lipoproteins and risk for coronary artery disease.
    Ballantyne CM
    Am J Cardiol; 1998 Nov; 82(9A):3Q-12Q. PubMed ID: 9819098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2017 Taiwan lipid guidelines for high risk patients.
    Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
    J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholesterol lowering in the management of coronary artery disease: the clinical implications of recent trials.
    Eisenberg DA
    Am J Med; 1998 Feb; 104(2A):2S-5S. PubMed ID: 9550499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New recommendations for the diagnosis and treatment of plasma lipid abnormalities.
    Schaefer EJ
    Nutr Rev; 1993 Aug; 51(8):246-53. PubMed ID: 8302497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Managing dyslipidemia in the high-risk patient.
    Stein EA
    Am J Cardiol; 2002 Mar; 89(5A):50C-57C. PubMed ID: 11900720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M; Roberts A; Davies S; Rees A
    Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of hypercholesterolemia: practice patterns for primary care providers and cardiologists.
    Bramlet DA; King H; Young L; Witt JR; Stoukides CA; Kaul AF
    Am J Cardiol; 1997 Oct; 80(8B):39H-44H. PubMed ID: 9372997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic factors clustering, lipoprotein cholesterol, apolipoprotein B, lipoprotein (a) and apolipoprotein E phenotypes in premature coronary artery disease in French Canadians.
    Weber M; McNicoll S; Marcil M; Connelly P; Lussier-Cacan S; Davignon J; Latour Y; Genest J
    Can J Cardiol; 1997 Mar; 13(3):253-60. PubMed ID: 9117913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57).
    Desai NR; Giugliano RP; Zhou J; Kohli P; Somaratne R; Hoffman E; Liu T; Scott R; Wasserman SM; Sabatine MS
    J Am Coll Cardiol; 2014 Feb; 63(5):430-3. PubMed ID: 24161333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of coronary heart disease through cholesterol reduction.
    Grundy SM
    Am Fam Physician; 1997 May; 55(6):2250-8. PubMed ID: 9149652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of risk factor management in progression and regression of coronary and femoral artery atherosclerosis.
    Glueck CJ
    Am J Cardiol; 1986 May; 57(14):35G-41G. PubMed ID: 3521250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Statins in primary prevention of coronary heart disease].
    Paulweber B
    Wien Med Wochenschr; 1999; 149(5-6):129-38. PubMed ID: 10408004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cholesterol 2001. Rationale for lipid-lowering in older patients with or without CAD.
    Aronow WS
    Geriatrics; 2001 Sep; 56(9):22-5, 28-30. PubMed ID: 11582971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Profiling risk and new therapeutic interventions: looking ahead.
    Shepherd J
    Am J Med; 1998 Feb; 104(2A):19S-22S. PubMed ID: 9550503
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.